Dimitri Krainc

List of Publications by Year
in descending order

99 papers	19,881 citations	50276 46 h-index	36028 97 g-index
105 all docs	105 docs citations	105 times ranked	31622 citing authors

#	Article	IF	Citations
1	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
2	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
3	Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity. Human Molecular Genetics, 2022, 31, 2424-2437.	2.9	11
4	Dysregulation of organelle membrane contact sites in neurological diseases. Neuron, 2022, 110, 2386-2408.	8.1	12
5	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. Neurology, 2022, 99, .	1.1	25
6	Replication assessment of NUS1 variants in Parkinson's disease. Neurobiology of Aging, 2021, 101, 300.e1-300.e3.	3.1	3
7	Modeling Brain Pathology of <scp>Niemannâ€Pick</scp> Disease Type C Using Patientâ€Derived Neurons. Movement Disorders, 2021, 36, 1022-1027.	3.9	4
8	Assessing the relationship between monoallelic PRKN mutations and Parkinsonâ€™s risk. Human Molecular Genetics, 2021, 30, 78-86.	2.9	36
9	<scp>MED27</scp> Variants Cause Developmental Delay, Dystonia, and Cerebellar Hypoplasia. Annals of Neurology, 2021, 89, 828-833.	5.3	14
10	Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy. Molecular Neurodegeneration, 2021, 16, 12.	10.8	13
11	Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinsonâ€™s disease. Nature Communications, 2021, 12, 1807.	12.8	99
12	Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. Journal of Clinical Investigation, 2021, 131, .	8.2	18
13	Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry, 2021, 65, 873-883.	4.7	4
14	Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological Î±-synuclein spread in the prodromal preformed fibrils model in young mice. Neurobiology of Disease, 2021, 159, 105513.	4.4	14
15	Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinsonâ€™s disease models. JCI Insight, 2021, 6, .	5.0	6
16	Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. Movement Disorders, 2021, 36, 2719-2730.	3.9	22
17	Identification of ASCL1 as a determinant for human iPSC-derived dopaminergic neurons. Scientific Reports, 2021, 11, 22257.	3.3	10
18	Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Human Molecular Genetics, 2020, 29, 716-726.	2.9	48

#	Article	IF	Citations
19	Organoid and pluripotent stem cells in Parkinsonâ€™s disease modeling: an expert view on their value to drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 427-441.	5.0	21
20	Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nature Neuroscience, 2020, 23, 15-20.	14.8	97
21	Astrocytes Protect Human Dopaminergic Neurons from Î±-Synuclein Accumulation and Propagation. Journal of Neuroscience, 2020, 40, 8618-8628.	3.6	57
22	Mitochondria-lysosome contacts regulate mitochondrial Ca ²⁺ dynamics via lysosomal TRPML1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19266-19275.	7.1	164
23	A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinsonâ€™s disease. Science Translational Medicine, 2020, 12, .	12.4	24
24	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 580634.	3.7	40
25	Gelator Length Precisely Tunes Supramolecular Hydrogel Stiffness and Neuronal Phenotype in 3D Culture. ACS Biomaterials Science and Engineering, 2020, 6, 1196-1207.	5.2	36
26	The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. Neurobiology of Disease, 2019, 132, 104545.	4.4	13
27	Lysosomal Regulation of Inter-mitochondrial Contact Fate and Motility in Charcot-Marie-Tooth Type 2. Developmental Cell, 2019, 50, 339-354.e4.	7.0	59
28	A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	12.4	77
29	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	3.9	62
30	Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration. Neurotherapeutics, 2019, 16, 611-634.	4.4	52
31	Increased Lysosomal Exocytosis Induced by Lysosomal Ca²⁺ Channel Agonists Protects Human Dopaminergic Neurons from Î±-Synuclein Toxicity. Journal of Neuroscience, 2019, 39, 5760-5772.	3.6	93
32	Regulation and Function of Mitochondriaâ€“Lysosome Membrane Contact Sites in Cellular Homeostasis. Trends in Cell Biology, 2019, 29, 500-513.	7.9	203
33	Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Movement Disorders, 2019, 34, 614-624.	3.9	37
34	Fluctuations in cell density alter protein markers of multiple cellular compartments, confounding experimental outcomes. PLoS ONE, 2019, 14, e0211727.	2.5	11
35	LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinsonâ€™s disease patients. Nature Communications, 2019, 10, 5570.	12.8	131
36	Conversion of Quinazoline Modulators from Inhibitors to Activators of Î²-Glucocerebrosidase. Journal of Medicinal Chemistry, 2019, 62, 1218-1230.	6.4	16

#	Article	IF	Citations
37	Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinsonâ€™s Disease. Trends in Neurosciences, 2019, 42, 140-149.	8.6	206
38	Recessive mutations in VPS13D cause childhood onset movement disorders. Annals of Neurology, 2018, 83, 1089-1095.	5.3	104
39	Î²-Glucocerebrosidase Modulators Promote Dimerization of Î²-Glucocerebrosidase and Reveal an Allosteric Binding Site. Journal of the American Chemical Society, 2018, 140, 5914-5924.	13.7	29
40	Mitochondriaâ€“lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature, 2018, 554, 382-386.	27.8	564
41	Molecular mechanisms of Î±-synuclein and GBA1 in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 51-60.	2.9	77
42	High priority publications on Parkinson's disease in 2017. Lancet Neurology, The, 2018, 17, 8-10.	10.2	0
43	Untangling alpha synuclein fibrils by graphene quantum dots. Movement Disorders, 2018, 33, 1673-1673.	3.9	4
44	Novel Approach to Tracking Mutant Huntingtin in Biosamples. Trends in Molecular Medicine, 2018, 24, 978-981.	6.7	0
45	Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain, 2018, 141, 3052-3064.	7.6	51
46	BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. PLoS ONE, 2018, 13, e0200344.	2.5	13
47	Acid ceramidase inhibition ameliorates Î±-synuclein accumulation upon loss of GBA1 function. Human Molecular Genetics, 2018, 27, 1972-1988.	2.9	53
48	LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5576-5581.	7.1	115
49	Mutant Huntingtin Secretion in Neuro2A Cells and Rat Primary Cortical Neurons. Bio-protocol, 2018, 8, .	0.4	4
50	Lysosomal Proteins as a Therapeutic Target in Neurodegeneration. Annual Review of Medicine, 2017, 68, 445-458.	12.2	23
51	Î±-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nature Medicine, 2017, 23, 1-13.	30.7	688
52	The Parkinsonâ€™s disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics, 2017, 26, ddw413.	2.9	35
53	Functional assays for the assessment of the pathogenicity of variants in GOSR2, an ER-to-Golgi SNARE involved in progressive myoclonus epilepsies. DMM Disease Models and Mechanisms, 2017, 10, 1391-1398.	2.4	11
54	A PDE10A de novo mutation causes childhoodâ€onset chorea with diurnal fluctuations. Movement Disorders, 2017, 32, 1646-1647.	3.9	13

#	Article	IF	Citations
55	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Human Molecular Genetics, 2017, 26, 4861-4872.	2.9	100
56	Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinsonâ€™s disease. Science, 2017, 357, 1255-1261.	12.6	600
57	Mutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway. Journal of Neuroscience, 2017, 37, 9000-9012.	3.6	64
58	Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies. Nature Communications, 2017, 8, 1908.	12.8	43
59	Inhibition of PIP4KÎ³ ameliorates the pathological effects of mutant huntingtin protein. ELife, 2017, 6, .	6.0	49
60	Micropatterning Facilitates the Longâ€Term Growth and Analysis of iPSCâ€Derived Individual Human Neurons and Neuronal Networks. Advanced Healthcare Materials, 2016, 5, 1894-1903.	7.6	18
61	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences, 2016, 73, 3205-3215.	5.4	37
62	Design and Synthesis of Potent Quinazolines as Selective Î²-Glucocerebrosidase Modulators. Journal of Medicinal Chemistry, 2016, 59, 8508-8520.	6.4	16
63	Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinsonâ€™s Disease. Cell Stem Cell, 2016, 19, 709-724.	11.1	371
64	Human Neuron Cultures: Micropatterning Facilitates the Longâ€Term Growth and Analysis of iPSCâ€Derived Individual Human Neurons and Neuronal Networks (Adv. Healthcare Mater. 15/2016). Advanced Healthcare Materials, 2016, 5, 1893-1893.	7.6	0
65	Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders, 2016, 31, 1610-1618.	3.9	47
66	Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and Î±-Synuclein Accumulation. Stem Cell Reports, 2016, 7, 664-677.	4.8	164
67	Activation of Â-Glucocerebrosidase Reduces Pathological Â-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Journal of Neuroscience, 2016, 36, 7693-7706.	3.6	220
68	Challenges to neurology residency education in today's health care environment. Annals of Neurology, 2016, 80, 315-320.	5.3	9
69	Identification of TMEM230 mutations in familial Parkinson's disease. Nature Genetics, 2016, 48, 733-739.	21.4	146
70	Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence. Analytical Chemistry, 2016, 88, 2399-2405.	6.5	26
71	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
72	Characterization of the complex formed by Î²-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3791-3796.	7.1	45

#	Article	IF	Citations
73	Î±-Synucleinâ€“induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1931-1936.	7.1	292
74	Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway. Journal of Neuroscience, 2016, 36, 2425-2437.	3.6	115
75	Development of targeted therapies for Parkinson's disease and related synucleinopathies. Journal of Lipid Research, 2014, 55, 1996-2003.	4.2	17
76	Long-term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease. JAMA - Journal of the American Medical Association, 2014, 311, 617.	7.4	8
77	Alzheimer GeneAPOEÎµ4 Linked to Brain Development in Infants. JAMA - Journal of the American Medical Association, 2014, 311, 298.	7.4	8
78	LIMP-2 expression is critical for Î²-glucocerebrosidase activity and Î±-synuclein clearance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15573-15578.	7.1	109
79	ATP13A2/PARK9 Regulates Secretion of Exosomes and Î±-Synuclein. Journal of Neuroscience, 2014, 34, 15281-15287.	3.6	148
80	Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Human Molecular Genetics, 2014, 23, 2791-2801.	2.9	137
81	The Glycolytic Enzyme, GPI, Is a Functionally Conserved Modifier of Dopaminergic Neurodegeneration in Parkinsonâ€™s Models. Cell Metabolism, 2014, 20, 145-157.	16.2	82
82	Phosphatase and Tensin Homolog (PTEN)-induced Putative Kinase 1 (PINK1)-dependent Ubiquitination of Endogenous Parkin Attenuates Mitophagy. Journal of Biological Chemistry, 2013, 288, 2223-2237.	3.4	199
83	Identification and Rescue of Î±-Synuclein Toxicity in Parkinson Patientâ€“Derived Neurons. Science, 2013, 342, 983-987.	12.6	416
84	Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. Cell Stem Cell, 2013, 13, 691-705.	11.1	613
85	Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited Î±-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics, 2013, 22, 2067-2082.	2.9	124
86	Pharmacological Upregulation of PGC1Î± in Oligodendrocytes: Implications for Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 101-105.	1.9	7
87	Translating new research findings into clinical practice. Nature Reviews Neurology, 2012, 8, 65-66.	10.1	2
88	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
89	Identification of novel ATP13A2 interactors and their role in Î±-synuclein misfolding and toxicity. Human Molecular Genetics, 2012, 21, 3785-3794.	2.9	66
90	Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, Î±-Synuclein Accumulation, and Neurotoxicity. Journal of Neuroscience, 2012, 32, 4240-4246.	3.6	245

#	Article	IF	Citations
91	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	12.4	444
92	Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. Journal of Neuroscience, 2011, 31, 5970-5976.	3.6	348
93	Gaucher Disease Glucocerebrosidase and Î±-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell, 2011, 146, 37-52.	28.9	1,097
94	Pathogenic effects of novel mutations in the Pâ€type ATPase ATP13A2 (PARK9) causing Kuforâ€Rakeb syndrome, a form of earlyâ€onset parkinsonism. Human Mutation, 2011, 32, 956-964.	2.5	105
95	Clearance of Mutant Proteins as a Therapeutic Target in Neurodegenerative Diseases. Archives of Neurology, 2010, 67, 388-92.	4.5	39
96	Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation. Cell, 2009, 137, 60-72.	28.9	367
97	Transcriptional Repression of PGC-1Î± by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell, 2006, 127, 59-69.	28.9	912
98	Transcriptional Abnormalities in Huntington's Disease. , 2006, , 417-440.		1
99	Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science, 2002, 296, 2238-2243.	12.6	638